<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30338462</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>17</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1932-2267</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>12</Volume>                    <Issue>6</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Dec</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of cancer survivorship : research and practice</Title>                <ISOAbbreviation>J Cancer Surviv</ISOAbbreviation>            </Journal>            <ArticleTitle>Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>794-802</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11764-018-0716-6</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate the implications of a cancer diagnosis on medication adherence for pre-existing comorbid conditions, we explored statin adherence patterns prior to and following a new diagnosis of breast, colorectal, or prostate cancer among a multi-ethnic cohort.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We identified adults enrolled at Kaiser Permanente Northern California who were prevalent statin medication users, newly diagnosed with breast, colorectal, or prostate cancer between 2000 and 2012. Statin adherence was measured using the proportion of days covered (PDC) during the 2-year pre-cancer diagnosis and the 2-year post-cancer diagnosis. Adherence patterns were assessed using generalized estimating equations, for all cancers combined and stratified by cancer type and race/ethnicity, adjusted for demographic, clinical, and tumor characteristics.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 10,177 cancer patients, statin adherence decreased from pre- to post-cancer diagnosis (adjusted odds ratio (OR<sub>adj</sub>):0.91, 95% confidence interval (95% CI):0.88-0.94). Statin adherence decreased from pre- to post-cancer diagnosis among breast (OR<sub>adj</sub>:0.94, 95% CI:0.90-0.99) and colorectal (OR<sub>adj</sub>:0.79, 95% CI:0.74-0.85) cancer patients. No difference in adherence was observed among prostate cancer patients (OR<sub>adj</sub>:1.01, 95% CI:0.97-1.05). Prior to cancer diagnosis, adherence to statins was generally higher among non-Hispanic whites and multi-race patients than other groups. However, statin adherence after diagnosis decreased only among these two populations (OR<sub>adj</sub>:0.85, 95% CI:0.85-0.92 and OR<sub>adj</sub>:0.86, 95% CI:0.76-0.97), respectively.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found substantial variation in statin medication adherence following diagnosis by cancer type and race/ethnicity among a large cohort of prevalent statin users in an integrated health care setting.</AbstractText>                <AbstractText Label="IMPLICATIONS FOR CANCER SURVIVORS" NlmCategory="CONCLUSIONS">Improving our understanding of comorbidity management and polypharmacy across diverse cancer patient populations is warranted to develop tailored interventions that improve medication adherence and reduce disparities in health outcomes.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Banegas</LastName>                    <ForeName>Matthew P</ForeName>                    <Initials>MP</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-6158-7162</Identifier>                    <AffiliationInfo>                        <Affiliation>Center for Health Research, Kaiser Permanente Northwest, 3800 N. Interstate Ave, Portland, OR, 97227-1110, USA. Matthew.P.Banegas@kpchr.org.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Emerson</LastName>                    <ForeName>Marc A</ForeName>                    <Initials>MA</Initials>                    <AffiliationInfo>                        <Affiliation>Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Adams</LastName>                    <ForeName>Alyce S</ForeName>                    <Initials>AS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Research, Kaiser Permanente, Oakland, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Achacoso</LastName>                    <ForeName>Ninah S</ForeName>                    <Initials>NS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Research, Kaiser Permanente, Oakland, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chawla</LastName>                    <ForeName>Neetu</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Research, Kaiser Permanente, Oakland, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Alexeeff</LastName>                    <ForeName>Stacey</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Research, Kaiser Permanente, Oakland, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Habel</LastName>                    <ForeName>Laurel A</ForeName>                    <Initials>LA</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Research, Kaiser Permanente, Oakland, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>U24 CA171524</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 CA098838</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>R01 CA098838</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 AG032249</GrantID>                    <Acronym>AG</Acronym>                    <Agency>NIA NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01AG032249</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>U24 CA1715</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>18</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Cancer Surviv</MedlineTA>            <NlmUniqueID>101307557</NlmUniqueID>            <ISSNLinking>1932-2259</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Pharmacother. 2010 Sep;44(9):1410-21</RefSource>                <PMID Version="1">20702755</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Manag Care Pharm. 2014 Jan;20(1):51-7</RefSource>                <PMID Version="1">24372460</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2013 Feb;138(1):225-33</RefSource>                <PMID Version="1">23358904</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2014 May 1;120(9):1290-314</RefSource>                <PMID Version="1">24343171</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Opin Pharmacother. 2009 Dec;10(18):2973-85</RefSource>                <PMID Version="1">19954271</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Epidemiol. 2012 Feb 15;175(4):250-62</RefSource>                <PMID Version="1">22223710</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Oncol Pract. 2015 Nov;11(6):429-34</RefSource>                <PMID Version="1">26105669</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Value Health. 2009 Jun;12(4):544-50</RefSource>                <PMID Version="1">19138308</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Vasc Health Risk Manag. 2014 Nov 06;10:615-25</RefSource>                <PMID Version="1">25395859</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Oncol Pract. 2016 Aug;12(8):e800-9</RefSource>                <PMID Version="1">27407167</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Gen Intern Med. 2007 Nov;22(11):1572-8</RefSource>                <PMID Version="1">17882499</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Care. 2014 Aug;52(8):695-703</RefSource>                <PMID Version="1">24988304</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacoeconomics. 2007;25(6):481-96</RefSource>                <PMID Version="1">17523753</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2007 Apr 18;99(8):592-600</RefSource>                <PMID Version="1">17440160</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am Health Drug Benefits. 2014 Oct;7(7):386-96</RefSource>                <PMID Version="1">25525495</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Support Care Cancer. 2010 Feb;19(2):211-20</RefSource>                <PMID Version="1">20076975</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Manag Care. 2008 Jun;14(6):388-92</RefSource>                <PMID Version="1">18554077</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Ther. 2009 Oct;31(10):2178-88; discussion 2150-1</RefSource>                <PMID Version="1">19922889</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Gen Intern Med. 2014 Apr;29(4):602-7</RefSource>                <PMID Version="1">24366395</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Crit Rev Oncol Hematol. 2005 Aug;55(2):117-42</RefSource>                <PMID Version="1">15890526</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cardiovasc Pharmacol Ther. 2015 Sep;20(5):447-56</RefSource>                <PMID Version="1">25827856</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Oncol Pract. 2011 Nov;7(6):371-4</RefSource>                <PMID Version="1">22379419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Pharmacother. 2009 Feb;43(2):185-93</RefSource>                <PMID Version="1">19193586</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncology (Williston Park). 2008 Aug;22(9):1052-5, discussion 1055, 1058, 1060</RefSource>                <PMID Version="1">18777955</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2017 Apr 15;123(8):1453-1463</RefSource>                <PMID Version="1">28218801</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2017 Jul 15;123(14):2726-2734</RefSource>                <PMID Version="1">28542734</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2016 Nov 15;316(19):2008-2024</RefSource>                <PMID Version="1">27838722</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Intern Med. 2007 Apr 23;167(8):781-7</RefSource>                <PMID Version="1">17452540</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2002 Jul 6;360(9326):7-22</RefSource>                <PMID Version="1">12114036</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):676-684</RefSource>                <PMID Version="1">28317314</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Support Care Cancer. 2010 May;18(5):651-5</RefSource>                <PMID Version="1">20140686</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2005 Nov 16;294(19):2437-45</RefSource>                <PMID Version="1">16287954</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816</RefSource>                <PMID Version="1">23440795</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2002 Nov 23;360(9346):1623-30</RefSource>                <PMID Version="1">12457784</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2009 Dec;20(12):1907-12</RefSource>                <PMID Version="1">19713244</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2018 Jul 10;36(20):2088-2100</RefSource>                <PMID Version="1">29775389</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pain Symptom Manage. 2008 May;35(5):535-43</RefSource>                <PMID Version="1">18243638</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Feb 1;32(4):306-11</RefSource>                <PMID Version="1">24366936</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2017 Jan;161(1):161-172</RefSource>                <PMID Version="1">27826756</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>MMWR Morb Mortal Wkly Rep. 2016 Sep 16;65(36):967-76</RefSource>                <PMID Version="1">27632693</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2016 Jul;66(4):337-50</RefSource>                <PMID Version="1">26891458</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2015 Jul;16(7):e333-41</RefSource>                <PMID Version="1">26149885</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Can J Cardiol. 2012 Sep-Oct;28(5):567-73</RefSource>                <PMID Version="1">22658124</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Health Care Financ Rev. 2008 Summer;29(4):41-56</RefSource>                <PMID Version="1">18773613</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Med Res. 2013 Jun;11(2):54-65</RefSource>                <PMID Version="1">23580788</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes Care. 2008 May;31(5):916-21</RefSource>                <PMID Version="1">18235050</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacoepidemiol Drug Saf. 2015 Jan;24(1):75-85</RefSource>                <PMID Version="1">24923811</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Intern Med. 2013 Jan 14;173(1):54-61</RefSource>                <PMID Version="1">23229831</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2002 Jul 24-31;288(4):455-61</RefSource>                <PMID Version="1">12132975</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Can J Cardiol. 2012 Sep-Oct;28(5):574-80</RefSource>                <PMID Version="1">22884278</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2004 Aug;5(8):489-96</RefSource>                <PMID Version="1">15288238</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer Epidemiol. 2012;2012:206414</RefSource>                <PMID Version="1">22956953</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Adherence</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>            <Keyword MajorTopicYN="N">Comorbidities</Keyword>            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>            <Keyword MajorTopicYN="N">Race/ethnicity</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pmc-release">                <Year>2019</Year>                <Month>12</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30338462</ArticleId>            <ArticleId IdType="doi">10.1007/s11764-018-0716-6</ArticleId>            <ArticleId IdType="pii">10.1007/s11764-018-0716-6</ArticleId>            <ArticleId IdType="pmc">PMC6238633</ArticleId>            <ArticleId IdType="mid">NIHMS1510032</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>